Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after Kite gene-modified cell therapy
2023-507041-28-00Phase 2Authorised
- Sponsor
- Kite Pharma
- Start
- Nov 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel, brexucabtagene autoleucel and KITE-363 in Non-hematologic malignancy and hematopoietic malignancies, sponsored by Kite Pharma. Primary endpoints: Late-onset targeted adverse events and serious adverse events possibly related to gene-modified cells, Neurologic disorders and 5 more. Planned start Nov 2022; status: authorised.
02
Drugs
axicabtagene ciloleucelbrexucabtagene autoleucelKITE-363
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on 2023-507041-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507041-28-00.